Evidence map›Paper›PMID 37417254›Full record

Observational studyPharmacology research & perspectives2023

Application of physiologically based pharmacokinetic modeling to understand real-world outcomes in patients receiving imatinib for chronic myeloid leukemia.

Josephine A Adattini, Jeffry Adiwidjaja, Annette S Gross, Andrew J McLachlan

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Pharmacology research & perspectives, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Josephine A AdattiniSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID 0000-0002-2575-7910
Jeffry AdiwidjajaSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID 0000-0002-6781-2113
Annette S GrossSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID 0000-0001-9567-0127
Andrew J McLachlanSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID 0000-0003-4674-0242
The University of Sydney · AU

Funding

GlaxoSmithKline Australia Peter Coates Postgraduate Scholarship in Ethnopharmacology
6 · The paper itself

Abstract

We aimed to use physiologically based pharmacokinetic (PBPK) modeling and simulation to predict imatinib steady-state plasma exposure in patients with chronic myeloid leukemia (CML) to investigate variability in outcomes. A validated imatinib PBPK model (Simcyp Simulator) was used to predict imatinib AUC

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveCytochrome P-450 CYP2C8Cytochrome P-450 CYP3AHumansImatinib MesylateCytochrome P-450 CYP2C8Cytochrome P-450 CYP3AImatinib Mesylateadverse drug reactionsdrug interactionsearly molecular responseexposure-responseimatinibphysiologically based pharmacokinetic (PBPK)simulation

Identifiers

PMID37417254
PMCPMC10326685
OpenAlexW4383482826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.